Skip to content
Back to announcement

20260903_MDLA_Public Expose_32144471_lamp1.pdf

Other Text extracted MDLA

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 14

Page 1
            Company
            Update

            1H 2026




PRIVATE & CONFIDENTIAL

Page 2
       Company Structure
                 PT Ekon Prima         Dra. Hetty Soetikno     PT Cakra Universal Persada      PT Vita Magna Trinita               Public


                    8,99%                    20,98%                    20,98 %                          23,98%                 25,07%




            Distribution & Medical Device




                                              75.00%                                                                               51.00%



           Distributor                Distributor              Marketing and Sales          Manufacturer               Digital Platform
           of pharmaceuticals,        of pharmaceuticals and   of medical devices and       of medical devices         to aggregate demand on
           medical devices, and       health products          marketing of                                            prescription drugs at
           health products for both   in Cambodia              pharmaceuticals                                         marketplace
           regular and JKN (BPJS) 2
           market in Indonesia
           Est. 1980                  Est. 2018                Est. 1981                    Est. 2020                  Est. 2022



PRIVATE & CONFIDENTIAL                                                                                                                          2

Page 3
                                                         With over 45 years of expertise, Medela Potentia has transformed into one of
           Milestone                                     Indonesia’s premier integrated distribution platforms, delivering a diverse range of
                                                         products nationwide — including our own line of manufactured medical devices




                    1980                             1981                  2011                  2018                       2022                   2024                  2025


        • 1980: Established as a trading       • 1981: acquired to    • 2011:             ▪ 2018: established in      ▪ 2022: established   ▪ 2024: established as   • 2025: Medela
         company focus on Pharmaceutical        strengthen our         established as a    Cambodia, marking           as a pharmacy         a medical device        Potentia Initial
                                                distribution           holding             MP’s first international    aggregator to         manufacturer            Public Offering
        • 1996: repositioned as a partner to                           company             expansion                   capture growing
         global healthcare players             • 2011: repositioned
                                                as a sales &                                                           e-commerce           ▪ 2025: first export
        • 2003: implemented ERP system                                                    ▪ 2020: implemented          demand.
                                                marketing arm for                          ERP system and
         and launched analytical business       medical devices and
         platform                                                                          analytical business
                                                launched its own                           platform
        • 2011: expanded into consumer          brand, Stardec.
         product distribution                                                             ▪ 2023: expand new
        • 2023: expanded into cosmetic,                                                    branches
         beauty and baby products
         distribution
        • 2023: Enhanced digital offerings
         through GPOS




PRIVATE & CONFIDENTIAL                                                                                                                                                                  3

Page 4
          Dedicated and experienced senior leadership team
          Management team with extensive experience, deep knowledge, and strong relationships
          with key principals and customers​




      Stanley Ch. Budihardja     Lukas Setia Atmaja        Juliwaty                                           Edbert Orotodan                Wimala Widjaja              Harris Lesmana Tjhin
          Commissioner       Independent Commissioner President Director                                          Director                      Director                President Director of DD
    Concurrently serve as Commissioner         Indonesian Citizen     Concurrently serve as AAM Director     Concurrently serve AAM       Concurrently serve as KITA            Indonesian Citizen
             of DD and DMM.                                                   and DAC Director.                  Commissioner.                 Commissioner.
            Indonesian Citizen                                                Indonesian Citizen               Indonesian Citizen            Indonesian Citizen




            Kansy W.                 Stephen Febianto                                                     Lim Budi                Tom Kimson               Luong Chan Huy           Ruth Retno Dewi
                                                                         Ivan Setiadi
         Director OF DD               Director of AAM                                                  Director of DAC           Director of DAC            Director of DAC          Director of KITA
                                                                    General Manager of DAC
           Indonesian Citizen            Concurrently serve as           Indonesian Citizen           Concurrently serve as       Cambodian Citizen         Cambodian Citizen         Indonesian Citizen
                                          Director of DMM.                                              Director of AAM.
                                          Indonesian Citizen                                           Indonesian Citizen


PRIVATE & CONFIDENTIAL                                                                                                                                                                                     4

Page 5
        Driving Growth Through Network Expansion
         Nationwide, Interconnected Distribution Network Supporting the Growth of Indonesia's Healthcare System

           INDONESIA                                               CAMBODIA                               Our strong commitment
           Our Infrastructure1                                     Our Infrastructure1
           35 Retail Warehouses
                                                                                                           to highest compliance
                                                                   3 Branches
           35 Sales Office (Branch)
                                                                   1 National Distribution Center (NDC)
           3 Representative Sales Office
           2 National Distribution Center (NDC)
                                                                   2 Retail Warehouses
           >800 Sales force                                        >40 Sales force
           Our Capacity1                                           Our Capacity
           >75,000 m³ storage capacity                             1,800 m³ storage capacity
           >2,000 m³ cold chain capacity
           Our Sale’s Channels
                 >4,000                 >23,000
                 Clinics                Pharmacies
                 >50,000                >3,000
                 Modern Trade           Government
                                        Institutions
                 >3,200
                 Hospitals              >1,300
                                        PBF & PAK
                 >20,000
                 Others




PRIVATE & CONFIDENTIAL                                                                                                             5

Page 6
      Expand Margin through Diversification
      into Medical Devices
      Business Model                               Manufacturing Facility


                          Own
                         Product




                Agency
                                                    • Inauguration: December
                                                      21st, 2023
                               Distribution         • Location: Jababeka II
                                                    • Land area: 5,985 sqm         • Storage area: 1,295 sqm (~1500 pallet)
                                                    • Building area: 4,800 sqm     • ISO 13485 : Wound care and surgical
                                                    • Production area: 3,600 sqm    supplies


      • Provide end to end solution for customer
                                                   ✔Strengthen own product business
        and business partners
                                                   ✔Government implemented a national health transformation to increase
      • Leveraging our relationship with channel    resilience in the medical device sector by supporting domestic manufacturing
        and healthcare professional                ✔Priority listing in the e-Katalog is given for products with a min. domestic
                                                    content of 40%, based on TKDN and BMP, fully implemented starting April 2022

PRIVATE & CONFIDENTIAL                                                                                                             6

Page 7
        External Awards and Recognitions
         S1 2026 Update

                                                                                            Public
                                                                                            Relations




      Indonesia Digital Marketing                  Indonesia Best CEO Award                      Indonesia Top Digital PR                 Indonesia Top Companies
             Champions                                 with Distinction                                  Award                                  Recognition
     SWA Media Group & Business Digest              SWA Media Group & Dunamis                           Info Brand & Tras n Co             Bloomberg & Indonesia Data

      PT Karsa Inti Tuju Askara (GoApotik)       The CEO of PT Medela Potentia Tbk, Mr.     PT Medela Potentia Tbk was recognized          PT Medela Potentia Tbk has been
     received an Excellent distinction for its   Krestijanto Pandji, was honored with the   with the Indonesia Top Digital PR Award        honoured with the Indonesia Top
    success in improving marketing and sales       Best CEO with Distinction award, the     2026, achieving a total score of 83.39%    Companies Recognition 2026 in the "Top
      performance. GoApotik achieved the           highest recognition bestowed upon        across Digital Media, Digital Sentiment,    Company in Resilient Healthcare Supply
    highest final score (88.9), outperforming        corporate leaders demonstrating                 and Digital Awareness.            Chain & Distribution Excellence" category.
     several other participating companies.         outstanding leadership excellence.




PRIVATE & CONFIDENTIAL                                                                                                                                                              7

Page 8
           S1 2026 Summary:
           Sustain Growth Amid Current Uncertainties


                         Maintain Overall
                         Revenue Growth        Strong Profit Growth
                                                                                New Principals
                             IDR 8.2T               IDR 226B
                                                                          in Each Business Segment
                              +10.1%                 +12.6%




                  Medical Device Own         Good Progress in Digital &
                Manufacturing Products:        AI Projects to improve     Continue The Commitment
                 Continue High Growth       Efficiency and Optimization        to Sustainability
                      Momentum




PRIVATE & CONFIDENTIAL                                                                               8

Page 9
              Growth Momentum Continues: Strong Top-Line, Improving
              Bottom-Line Efficiency
               In IDR Bio, unless otherwise stated

                        Net Sales                                 Gross Profit                                       EBITDA                                  Net Profit

                                                     1,000
     9, 000




                                                                                                                                   4.0%
                                                                                                       500                                  4.1%




                                                              9.6%
                                                                                                                                                   400




                                                                                    9.3%      10.0%
                                                                                                             3.9%
                                                      900




                                                                                                                                                                              2.8%
                                                                                                       450
     8, 000                                                                                                                                                                            3.0%


                                                                                                                                            3.9%

                                                                                                                                                   350

                                                                                                                                                         2.7%
                                                      800
                                                                                                       400

     7, 000



                                                                                              5.0%


                                                                                                                                            3.7%
                                                                                                                                                                                       2.5%
                                                                                                                                                   300


                                                      700
                                                                                                       350



     6, 000




                            Gr                        600
                                                                                              0.0%

                                                                                                       300
                                                                                                                                            3.5%
                                                                                                                                                   250

                                                                                                                                                                                       2.0%



     5, 000


                          +10.1%
                                                      500
                                                                                                       250                                  3.3%
                                                                                                                                                   200




     4, 000

                                         8,171                                                -5.0%


                                                                                                                                                                                       1.5%




                7,420                                                      Gr        762
                                                      400
                                                                                                       200




                                                               713       +6.8%                                             Gr
                                                                                                                                            3.1%
                                                                                                                                                   150


     3, 000




                                                                                              -10.0%
                                                                                                                                    325                             Gr
                                                                                                              292        +11.2%
                                                      300




                                                                                                                                                                  +12.6%
                                                                                                       150




                                                                                                                                                                               226
                                                                                                                                                                                       1.0%




     2, 000




                                                      200
                                                                                                       100
                                                                                                                                            2.9%
                                                                                                                                                   100

                                                                                                                                                          200
                                                                                              -15.0%


                                                                                                                                                                                       0.5%

                                                                                                                                            2.7%
     1, 000
                                                                                                                                                    50
                                                      100
                                                                                                        50




        -                                               -                                     -20.0%
                                                                                                        -                                   2.5%
                                                                                                                                                    -                                  0.0%




               S1'25                     S1'26                S1'25                 S1'26                    S1'25                S1'26                  S1'25               S1'26
                                                                Gross Profit     %GM to NS                      EBITDA      %EBITDA to NS                   PAT    %Net Profit to NS
                          Consolidated

               Double digit Top-line                         Lower %GP due to                                increasing EBITDA                           higher net profit
               Growth                                        principal and product                           margin trend                                growth than net sales
                                                             portfolio mix                                                                               growth


              Source : PT Medela Potentia Tbk and its subsidiaries unaudited S1’26 financial report
PRIVATE & CONFIDENTIAL                                                                                                                                                                        9

Page 10
        Distribution Business – Update S1 2026

                         Infrastructures Development                                     System Development                                                       New Principals


                                 New Medan Warehouse                 2026: Focus on Supply Chain Optimization
                                 • Acquired: 2023                                                                    Forecast Accuracy
                                 • Land size: 9,258m2
                                 • Facilities: 2000 pallet
                                 • Build Progress: 95%
                                 • Estimated Go Live: Q4 2026
                                                                     Data-driven Planning model
                                                                     to Improve Productivity and
                                                                     Optimization
                                                                                                                     100%

                                                                                                                                                      5         New Principals
                                                                                                                                                                Joined in 1H 2026
                                                                     • Feature: Anaplan with AI                     FY 24    FY 25     1H 26
                                                                       Optimizer Planning System
                                                                     • Improvement Result:                           Out of Stock
                                 New Land NDC2 – Jababeka I
                                 • Acquired: August 2025                 • Forecast Accuracy                         2%
                                 • Land size: 2,7 Ha                       incremental
            PLAN                 • Plan: Build Cold Storage, Start       • Out Of Stock reduction                                                     Ethical    Consumer Medical
                                   April 2026 – Go Live Q2 2027          • Transport cost efficiency                FY 24    FY 25     1H 26          Pharma      Health  Device
                                 • S1 2026 : Final Design Draft

                                 Electric Vehicle Van Project
                                 • S1-2026
                                                                     Digital algorithm to Drive
                                                                     Warehouse Productivity            1.2 00.000




                                                                                                       1.0 00.000
                                                                                                                    Warehouse Operations        500




                                                                                                                                                450




                                                                                                                                                400
                                                                                                                                                        1           3        1
                                     • Go Live April 2026            • Feature: Suggestion system       800 .000
                                                                                                                                                350




                                                                                                                                                300




                                     • Trial & Analysis 1 unit
                                                                                                        600 .000                                250




                                                                       to optimize order picking        400 .000
                                                                                                                                                200




                                                                                                                                                150




                                     • In-Town Coverage                operations                       200 .000
                                                                                                                                                100




                                                                                                                                                50




                                 • Plan S2-2026                      • Improvement Result:
                                                                                                               0                                0




                                                                                                                     FY 24   FY 25      1H 26
                                     • Add units for Jabotabek           • Incremental Output with                             Sales Order
                                        Branches                           no additional man power                             Man Power




PRIVATE & CONFIDENTIAL                                                                                                                                                              10

Page 11
       Medical Device Own Product – Update S1 2026

           Medical Device Manufacturing Update
                                                                  Growing Total Sales and             Deca Metric Medica:
           Product Portfolio                                      Hospital Coverage                   Production Output
                                                         20.000            Coverage             500
                                                                             +12%                                Total
                                                         15.000                                                 Output
                                                                                                400                              Production Output:
                                                         10.000                                                  +8%
                                                                             Sales                                               • Own Brand (Deca)
                                                                             +34%               300
                                                          5.000                                                                  • 3rd Party OEM
                                                             -                                  200                                 (start 2H 2024)
                                                                   1H 25              1H 26             1H 25            1H 26
                                                                     SALES           COVERAGE




           New SKUs Launched 1H 2026                                       Export Market
                                                                                                                 Plan S2 2026 – Own Product
                                                                             Cambodia:
                                                                             • First Export 5 Agustus 2025
                                                                                                                 •   New Launched Products: 4-5
                                                                               (Decafix, Decamed T)
                                                                                                                     Brands, Focus on Wound Care
                                                                             • Plan Repeat: Q3 2026
                                                                                                                     and OR Solution
                                                                                                                 •   New Export exploration –
                                                                                                                     ASEAN & Africa
           Stardec DecaCare 5 Liter   Stardec DecaFoam




PRIVATE & CONFIDENTIAL                                                                                                                                11

Page 12
       Digital B2B – S1 2026 Update:
       Growing Revenue and Coverage Reach
                                            Toserba                                                                              S1 2026 Results
                                           Principals
                                                                                                                   Coverage
                                                                                        300.000
                                                                                                                    +15%                           Value Added Services in
                                                                                                                                                  14.500
                                                                                                                                                  14.000
                                                                                        250.000                                                    Collaboration with
                                                                                                                                                  13.500
              Principals                     AAM                                                                                                  13.000
                                                                                        200.000
                                                                                        150.000
                                                                                        100.000
                                                                                                                     Sales
                                                                                                                     +20%
                                                                                                                                                   18
                                                                                                                                                  12.500
                                                                                                                                                  12.000
                                                                                                                                                  11.500
                                                                                                                                                  11.000
                                                                                                                                                          Principals (3 new)

                                                                                                          S1 25
                                                                                                               SALES
                                                                                                                                 S1 26
                                                                                                                             COVERAGE
                                                                                                                                                   40       Brands (3 new)



                                                                                                             2026 Strategic Objectives: Excellence & Expansion

                                                                                                  • Key Objective: Increase digital B2B coverage and sales contribution by double-
                                                                                                    digit growth through continuous operational excellence and commercial
        Vet                   Others        Hospital         Clinics          Apotek                expansion.
                                                                                                  • Operational Excellence: Improve pricing and promotion features (done S1
                                                                                                    2026) and expand channels through HIS integration (continue in S2 2026).
   Active: >200            Active: >900   Active: >900   Active: >1,200   Active: >11,500         • Commercial Expansion: Deepen brand collaborations and aggressively grow
                                                                                                    Toserba sales and expand digital B2B platform to new channels.



PRIVATE & CONFIDENTIAL                                                                                                                                                               12

Page 13
       Delivering a Better Healthcare:
       Commitment to ESG S1 2026 Update

                         Environmental                                           Social                                 Governance

         Solar Panel Implementation                                                                 Consistency in Action: PT Anugrah Argon
                                                                                                    Medica and BPOM Continue Strengthening
                                                                                                    Good Distribution Practice (CDOB)
                                                            • 8.505 people impacted.                Implementation Nationwide
                                                            • 56 community-focused activities.      S1 2026: 8 Cities | 836 Pharmacists
                                                            • 27 cities. 18 provinces. 6 islands.
         Implementation of renewable energy by installing
         a 90 kWp rooftop solar power system at the
         Tangerang Branch.

         EV Implementation
         • 13 Cities
         • 15 Branches
         • 106 EV Bikes
         • 1 EV Car

                                                                                                    2026 Estimation: 12 Cities +1000 Partners




PRIVATE & CONFIDENTIAL                                                                                                                          13

Page 14
       Company Strategy S2 2026
                         Continue Driving Business Growth
             1            •   New Principal Exploration: Existing & New Segments
                          •   Strengthen distribution coverage: OOP & BPJS Market, including new channel exploration
                          •   Exploring prudently for presence in some countries within ASEAN


                         Strengthening and Modernizing Distribution System
             2            •   Capacity Expansion: Cold Chain & Non Cold Chain
                          •   AI implementation in Business Process: Growth Exploration, Improve Productivity & Accuracy
                          •   Exploration of Automatic System in Warehouse Infrastructure


                         Expanding Medical Device Portfolio
             3            •   Strengthen Own Product “Stardec” Portfolio: New Products Launch
                          •   Continue exploring export market for “Stardec” own product to countries within ASEAN & Africa Region
                          •   Expanding “Agency” Product Portfolio: Orthopedics, Minimally Invasive Surgery, and Oncology


                         Commitment to ESG
             4            •   Climate and Energy: Lower Emission & Renewable Energy
                          •   Continue the Community Engagement & Contribution thru Argon Peduli




PRIVATE & CONFIDENTIAL                                                                                                               14


File

File Open PDF
Source IDX
Size3.27 MB
Published3 Sep 2026
Pages14
Characters39,292
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 15 people and organisations named in the text · linked when the evidence is strong

linked org PT Vita Magna Trinita p.2
linked org Medela Potentia p.3 ×12
linked person Stanley Ch. Budihardja p.4
linked person Lukas Setia Atmaja p.4
linked person Edbert Orotodan p.4
linked person Wimala Widjaja p.4
linked person Krestijanto Pandji p.7
linked org Deca Metric Medica p.11
linked org PT Anugrah Argon Medica p.13
possible org PT Ekon Prima p.2
possible person Dra. Hetty Soetikno p.2
possible org PT Cakra Universal Persada p.2
unresolved person Indonesian Citizen · Commissioner p.4
unresolved person Concurrently · Director p.4
unresolved org PT Karsa Inti Tuju Askara p.7

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

Other files in this announcement 1

↑↓ select ↵ open ⇧↵ see every result